Status:
WITHDRAWN
IL-1RA, Acute Exercise, and Beta-cell Function
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
Subjects (N=48) with poorly-controlled type 2 diabetes (HbA1c\>7%) will be assigned to one of the 4 following interventions in a randomised, parallel group design: \[I\] Control (placebo injection; no...
Eligibility Criteria
Inclusion
- Type 2 diabetes with HbA1c \>7%
Exclusion
- HbA1c \>7%
- Age \<30 or \>80 y
- BMI \<25 or \>40 kg/m2
- Pregnancy
- Evidence of chronic haematological/renal/hepatic/pulmonary/heart disease
- \>2kg weight change in prior 6 months
- Alcohol consumption (men: \>14 drinks/week; women: \>7 drinks/week)
- Smoking
- Physical activity of \>150 min/week
- Contraindication to exercise
- Contraindication to use of anakinra
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02310009
Start Date
December 1 2014
End Date
July 30 2015
Last Update
February 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark